Microchip Technology Incorporated, in the first quarter of fiscal 2010, reached a settlement agreement with LSI Logic Corporation to resolve patent infringement dispute.
On April 18, 2008, LSI Logic and its…
Allergan Inc.’s patent infringement complaint against Barr Laboratories, Inc., is pending in the U.S. District Court for the District of Delaware.
In March 2009, the Company received a paragraph 4 invalidity…
Allergan Inc.’s consolidated patent infringement suit against Exela PharmSci Inc. and Apotex Inc. is ongoing in the U.S. District Court for the District of Delaware.
In February 2007, the Company and…
Pfizer Inc. pursues a patent infringement action against Matrix Laboratories Limited, Mylan Inc., and another subsidiary of Mylan.
In May 2009, Matrix, a subsidiary of Mylan, notified the Company that it…
A trial date has been set for April 5, 2010, on Forest Laboratories Inc.’s patent infringement complaint against generic manufacturers of Namenda, the Company’s N-methyl-D-aspartate.
During the third quarter of fiscal…
Allergan Inc., Endo Pharmaceuticals Solutions, Inc., and Supernus Pharmaceuticals, Inc. pursue a patent infringement complaint against Watson, Watson Laboratories, Inc. — Florida, and Watson Pharma, Inc.
In June 2009, the Company…
The U.S. District Court for the Central District of California has scheduled an Oct. 12, 2010 trial date for Allergan Inc.’s complaint against eight defendants, alleging the infringement of U.S.…
Pfizer Inc. said it will file an action in the Canadian Federal Court in Toronto to prevent approval of Genpharm Inc.’s proposed generic product.
In July 2009, Genpharm Inc. served notice…
Microchip Technology Incorporated, during the three months ended June 30, 2009, agreed to the terms of a patent license with an unrelated third-party.
The Company signed an agreement on July 9,…
The settlement of the patent infringement suit captioned “Forest Laboratories, Inc. et al. v. Caraco Pharmaceutical Laboratories, Ltd. et al.,” remains subject to review by the U.S. Federal Trade Commission.
In…